Future Directions in Castrate-Resistant Prostate Cancer Therapy
- 1 December 2010
- journal article
- review article
- Published by Elsevier BV in Clinical Genitourinary Cancer
- Vol. 8 (1), 37-46
- https://doi.org/10.3816/cgc.2010.n.006
Abstract
No abstract availableThis publication has 88 references indexed in Scilit:
- The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label studyBritish Journal of Cancer, 2010
- PARP inhibition: PARP1 and beyondNature Reviews Cancer, 2010
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)Cancer, 2009
- Synthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEMBO Molecular Medicine, 2009
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell CarcinomaThe New England Journal of Medicine, 2009
- Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449The New England Journal of Medicine, 2009
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acidThe Prostate, 2008
- Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonistsProceedings of the National Academy of Sciences of the United States of America, 2007
- Clusterin inhibits apoptosis by interacting with activated BaxNature, 2005